Endocrinology · Familial Non-Autoimmune Hyperthyroidism

The Biology of FNAH

At a Glance

Familial non-autoimmune hyperthyroidism (FNAH) is caused by an activating change in the TSHR gene that leaves the thyroid’s signaling switch on. The result is persistent excess thyroid hormone, assessed with antibody testing, scans, and genetic testing.

To understand Familial Non-Autoimmune Hyperthyroidism (FNAH), you have to look closely at the “control panel” of your thyroid cells. While it shares symptoms with more common conditions like Graves’ disease, the biology behind FNAH is entirely different. It isn’t caused by an outside attack from your immune system; instead, it is caused by a permanent change in the thyroid’s internal hardware ^[1].

The Stuck Switch: Constitutive Signaling

Every thyroid cell has a TSH Receptor (TSHR) on its surface. Normally, this receptor acts like a high-tech doorbell. When your brain determines you need more thyroid hormone, it releases TSH (the “finger” that presses the bell). This triggers a messenger inside the cell called cAMP (cyclic adenosine monophosphate) ^[2]^[1]. This messenger tells the cell to start producing and releasing thyroid hormones.

In FNAH, a genetic mutation in the TSHR gene changes the shape of this receptor ^[3]. Even without any TSH present to “press the bell,” the receptor often remains active. This is known as constitutive activation ^[2]. Because the receptor is frequently sending the cAMP signal, your thyroid cells continue to grow and churn out hormones, regardless of what your body actually needs ^[4]^[5].

FNAH vs. Graves’ Disease

Because both conditions result in too much thyroid hormone, they are frequently confused. However, their biological “blueprints” are distinct:

Feature	FNAH	Graves’ Disease
Primary Cause	Inherited or new genetic mutation in the TSHR gene ^[1].	An autoimmune attack where the body makes TRAb (antibodies) ^[6].
Antibodies	Usually TRAb-negative. Your immune system is not the primary driver ^[7].	Usually TRAb-positive. Antibodies are usually found in the blood ^[1].
Eye/Skin Symptoms	Generally absent. No bulging eyes (orbitopathy) or skin thickening ^[6].	Common. Many patients experience eye inflammation or “grittiness” ^[8].
Duration	Lifelong and persistent. It does not go into remission on its own ^[9].	Can be temporary. Some patients achieve long-term remission ^[10].

Navigating the “Mimics”

FNAH isn’t the only condition that can cause hyperthyroidism without antibodies. Doctors must rule out other “mimics” that can look similar:

Mimic Condition	What it is	How it differs from FNAH
Toxic Adenoma	A single, non-cancerous lump (nodule) that becomes overactive ^[11].	Scans typically show one “hot” spot, whereas FNAH often involves the whole gland (though FNAH scans can vary) ^[11].
Toxic Multinodular Goiter	Multiple overactive lumps, usually developing slowly over decades in older adults ^[12].	Scans show multiple nodules rather than a genetic whole-gland mechanism ^[12].
Disseminated Thyroid Autonomy	Many small areas of the thyroid start working independently ^[11]^[12].	Extremely difficult to distinguish from FNAH without genetic testing ^[11].
Thyroiditis	Temporary inflammation releasing stored hormone.	Usually resolves; scans show very low activity rather than overactivity.

The Role of Genetic Testing

You might wonder why a simple blood test isn’t enough. While a negative antibody test (TRAb-negative) is a major clue, it isn’t definitive proof of FNAH. Some people with Graves’ disease have very low antibody levels that don’t show up on standard tests (sometimes called “seronegative Graves”) ^[13]^[12].

Finding a pathogenic or likely pathogenic activating variant through germline genetic testing strongly supports the diagnosis of FNAH ^[14]. This test looks at your DNA to see if the TSHR mutation is present. If found, it supports that your hyperthyroidism is a genetic trait rather than a temporary immune reaction ^[1]^[9]. However, genetic testing has limitations: a negative panel does not perfectly exclude a genetic cause. This is why reviewing your results with a genetic counselor is highly recommended ^[14].

Common questions in this guide

What causes familial non-autoimmune hyperthyroidism?

FNAH is caused by an activating change in the TSHR gene, which controls a receptor on thyroid cells. The altered receptor can remain switched on even without TSH, sending signals that make the thyroid produce too much hormone.

How is FNAH different from Graves’ disease?

FNAH is driven by a TSHR gene change, while Graves’ disease is caused by an autoimmune attack involving thyroid-stimulating antibodies. FNAH is usually antibody-negative, generally does not cause Graves-related eye or skin findings, and tends to remain persistent rather than entering remission on its own.

Can a negative TRAb test prove that I have FNAH?

No. A negative TRAb test is an important clue, but some people with Graves’ disease have antibody levels too low for standard tests to detect. Doctors combine antibody results with symptoms, thyroid scans, family history, and genetic testing.

What can genetic testing show in FNAH?

Germline genetic testing examines your DNA for a disease-causing or likely disease-causing activating TSHR variant. Finding one strongly supports FNAH, but a negative genetic panel does not completely rule out a genetic cause, so genetic counseling can help explain the result.

Can a thyroid scan tell FNAH apart from a toxic nodule?

FNAH often affects the thyroid more diffusely, whereas a toxic adenoma usually appears as one overactive spot and toxic multinodular goiter shows several overactive nodules. Scan patterns can vary and may overlap with other conditions, so genetic and laboratory results may also be needed.

Can FNAH run in families?

Yes. The TSHR change may be inherited, although it can also occur as a new genetic change in someone with no known family history. A genetic counselor can discuss whether relatives should consider evaluation or testing.

Get notified when new evidence is published on Familial hyperthyroidism due to mutations in TSH receptor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (14)

1
TSHR Gly413Ser in familial nonautoimmune hyperthyroidism: a case report.
Kelp O, Førsvoll J, Bischof F, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2026; doi:10.1515/jpem-2025-0617.
PMID: 42665942
2
Familial Non-Autoimmune Hyperthyroidism Caused by an Extracellular Domain Variant (p.Leu267Phe) of the TSH Receptor.
Shimura K, Ichihashi Y, Abe K, et al.
Hormone research in paediatrics 2026; (99(5)):623-631 doi:10.1159/000544836.
PMID: 39987906
3
Autoantibody mimicry of hormone action at the thyrotropin receptor.
Faust B, Billesbølle CB, Suomivuori CM, et al.
Nature 2022; (609(7928)):846-853 doi:10.1038/s41586-022-05159-1.
PMID: 35940205
4
Structural-Functional Features of the Thyrotropin Receptor: A Class A G-Protein-Coupled Receptor at Work.
Kleinau G, Worth CL, Kreuchwig A, et al.
Frontiers in endocrinology 2017; (8()):86 doi:10.3389/fendo.2017.00086.
PMID: 28484426
5
Genotype-Phenotype Correlation in Germline TSH Receptor Activating Mutation Associated Hyperthyroidism: A Systematic Review.
Yamichannaiah C, Memon SS, Sarathi V, et al.
Clinical endocrinology 2025; (103(2)):119-128 doi:10.1111/cen.15288.
PMID: 40470728
6
Novel presentation of the c.1856A > G (p.Asp619Gly) TSHR gene-activating variant: relapsing hyperthyroidism in three subsequent generations manifesting in early childhood and an in vitro functional study.
Bezdicka M, Kleiblova P, Soucek J, et al.
Hormones (Athens, Greece) 2021; (20(4)):803-812 doi:10.1007/s42000-021-00299-x.
PMID: 34142359
7
An A627V-activating mutation in the thyroid-stimulating hormone receptor gene in familial nonautoimmune hyperthyroidism.
Shin JH, Seo GH, Oh SH, et al.
Annals of pediatric endocrinology & metabolism 2020; (25(4)):282-286 doi:10.6065/apem.2040076.038.
PMID: 33401884
8
Controversies Surrounding IGF-I Receptor Involvement in Thyroid-Associated Ophthalmopathy.
Smith TJ
Thyroid : official journal of the American Thyroid Association 2025; (35(3)):232-244 doi:10.1089/thy.2024.0606.
PMID: 39909461
9
Report of a family with three generations of undiagnosed familial nonautoimmune hyperthyroidism.
Stephenson A, Punjwani Z, Eszlinger M, et al.
Endocrinology, diabetes & metabolism case reports 2021; (2021()).
PMID: 34866058
10
The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves' Disease.
Baek HS, Lee J, Jeong CH, et al.
Journal of the Endocrine Society 2022; (6(5)):bvac023 doi:10.1210/jendso/bvac023.
PMID: 35441120
11
Hyperfunctioning Papillary Thyroid Carcinoma with a BRAF Mutation: The First Case Report and a Literature Review.
Shinkai S, Ohba K, Kakudo K, et al.
European thyroid journal 2021; (10(3)):262-267 doi:10.1159/000513552.
PMID: 34178713
12
Mild Thyrotoxicosis due to Seronegative Graves' Disease or Disseminated Thyroid Autonomy.
Charbonne G, Hallak F, Rivera Cruz AE, McDonald SD
AACE clinical case reports 2025; (11(2)):102-106 doi:10.1016/j.aace.2024.12.002.
PMID: 40201472
13
Diagnostic discordance and performance of third-generation competitive TRAb vs. sandwich TSI ELISA in the diagnosis of Graves' disease.
Naser Abed M, Abdul Khaliq RJ
Scandinavian journal of clinical and laboratory investigation 2026; (86(4)):355-360 doi:10.1080/00365513.2026.2669918.
PMID: 42112605
14
Inheritable and sporadic non-autoimmune hyperthyroidism.
Ferraz C, Paschke R
Best practice & research. Clinical endocrinology & metabolism 2017; (31(2)):265-275 doi:10.1016/j.beem.2017.04.005.
PMID: 28648513

This page explains the biology and genetic testing of FNAH for informational purposes only and is not medical advice. An endocrinologist and genetic counselor can interpret your results and discuss diagnosis and treatment.